SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate ...Middle East

PR Newswire - News
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicity data from the Phase II study. SK bioscience and Sanofi plan to start Phase III in H1 2024. SEONGNAM, South Korea, June 29, 2023 /PRNewswire/ -- SK...

Hence then, the article about sk bioscience sanofi announce positive results from phase ii study of 21 valent pneumococcal conjugate vaccine candidate was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate )

Apple Storegoogle play

Last updated :

Also on site :